Mission Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mission Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Buy	8,170 +4,075	+100%	+$1.81M	0.05%	202
2026 Q1	$1.83M	Buy	4,095 +39	+1%	+$18.2K	0.04%	227
2025 Q4	$1.84M	Buy	4,056 +89	+2%	+$38.4K	0.04%	224
2025 Q3	$1.55M	Sell	3,967 -1,742	-31%	-$728K	0.03%	250
2025 Q2	$2.54M	Sell	5,709 -1,202	-17%	-$554K	0.05%	185
2025 Q1	$3.35M	Buy	6,911 +859	+14%	+$400K	0.08%	136
2024 Q4	$2.44M	Sell	6,052 -575	-9%	-$267K	0.06%	163
2024 Q3	$3.08M	Buy	6,627 +815	+14%	+$391K	0.07%	138
2024 Q2	$2.72M	Sell	5,812 -1,995	-26%	-$866K	0.07%	144
2024 Q1	$3.26M	Buy	7,807 +2,914	+60%	+$1.23M	0.09%	130
2023 Q4	$1.99M	Buy	4,893 +212	+5%	+$78.3K	0.06%	148
2023 Q3	$1.63M	Buy	4,681 +70	+2%	+$24.5K	0.06%	157
2023 Q2	$1.62M	Buy	4,611 +21	+0.5%	+$7.08K	0.06%	154
2023 Q1	$1.45M	Buy	4,590 +64	+1%	+$19.2K	0.06%	171
2022 Q4	$1.31M	Buy	4,526 +164	+4%	+$50K	0.06%	167
2022 Q3	$1.26M	Buy	4,362 +96	+2%	+$27.6K	0.07%	156
2022 Q2	$1.2M	Buy	4,266 +658	+18%	+$176K	0.06%	168
2022 Q1	$942K	Buy	3,608 +492	+16%	+$117K	0.04%	211
2021 Q4	$684K	Sell	3,116 -55	-2%	-$10.7K	0.03%	250
2021 Q3	$575K	Buy	3,171 +57	+2%	+$11.1K	0.03%	261
2021 Q2	$628K	Buy	3,114 +63	+2%	+$13.2K	0.03%	250
2021 Q1	$656K	Buy	3,051 +490	+19%	+$108K	0.04%	211
2020 Q4	$605K	Buy	2,561 +332	+15%	+$76.2K	0.04%	196
2020 Q3	$607K	Buy	2,229 +44	+2%	+$12.1K	0.05%	170
2020 Q2	$634K	Buy	2,185 +52	+2%	+$14.1K	0.05%	159
2020 Q1	$508K	Sell	2,133 -7	-0.3%	-$1.61K	0.06%	160
2019 Q4	$469K	Buy	2,140 +125	+6%	+$25.3K	0.05%	189
2019 Q3	$341K	Sell	2,015 -459	-19%	-$81.2K	0.04%	212
2019 Q2	$454K	Sell	2,474 -264	-10%	-$46.2K	0.05%	181
2019 Q1	$504K	Buy	2,738 +231	+9%	+$42.7K	0.06%	169
2018 Q4	$415K	Buy	2,507 +465	+23%	+$80.6K	0.05%	170
2018 Q3	$394K	Hold	2,042	–	–	0.05%	176
2018 Q2	$347K	Buy	+2,042	New	+$317K	0.05%	177

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Mission Wealth Management's VRTX Position: Q2 2026 in Review

Mission Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 100% in Q2 2026, buying an estimated $1.81M and bringing the position to 8,170 shares worth $4.06M. The position accounts for 0.05% of the portfolio, ranked #202.

Mission Wealth Management first reported a position in VRTX in Q2 2018 and has held it in 33 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mission Wealth Management held 8,170 shares of Vertex Pharmaceuticals worth $4.06M as of Q2 2026.
Mission Wealth Management bought 4,075 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.81M.
Vertex Pharmaceuticals made up 0.05% of Mission Wealth Management's portfolio in Q2 2026, its #202 holding.
Mission Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.